论文部分内容阅读
目的观察卡维地洛对慢性心力衰竭(CHF)的临床疗效。方法76例慢性心力衰竭患者随机分为治疗组和对照组,2组均给予常规抗心力衰竭治疗,治疗组加用卡维地洛。疗程为24周。观察并比较治疗后2组在纽约心脏协会(NY-HA)心功能分级、左室射血分数(LVEF)、6 min步行距离、心率、血压及病死率。结果治疗组较对照组NYHA心功能分级、LVEF、6 min步行距离均明显改善,血压、心率明显降低,病死率下降。结论在常规治疗基础上加用卡维地洛治疗慢性心力衰竭,可明显增加LVEF、改善心脏功能,增加6 min步行距离,改善运动耐量,提高患者生存率,且不良反应小。
Objective To observe the clinical effect of carvedilol on chronic heart failure (CHF). Methods 76 patients with chronic heart failure were randomly divided into treatment group and control group. Both groups were given routine anti-heart failure treatment. The treatment group was given carvedilol. Treatment for 24 weeks. The NYHA cardiac function classification, left ventricular ejection fraction (LVEF), walking distance of 6 min, heart rate, blood pressure and mortality were observed and compared between the two groups after treatment. Results Compared with the control group, NYHA functional class, NYHA functional class, LVEF, 6 min walking distance were significantly improved, blood pressure, heart rate and mortality decreased significantly. Conclusion Carvedilol treatment based on routine treatment of chronic heart failure can significantly increase LVEF, improve cardiac function, increase 6 min walk distance, improve exercise tolerance, improve patient survival, and adverse reactions.